Movatterモバイル変換


[0]ホーム

URL:


US20030157174A1 - Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component - Google Patents

Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
Download PDF

Info

Publication number
US20030157174A1
US20030157174A1US10/239,222US23922202AUS2003157174A1US 20030157174 A1US20030157174 A1US 20030157174A1US 23922202 AUS23922202 AUS 23922202AUS 2003157174 A1US2003157174 A1US 2003157174A1
Authority
US
United States
Prior art keywords
granule
enteric coat
enteric
water repellent
repellent agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/239,222
Inventor
Takayuki Tsukuda
Hidekazu Syodai
Hajime Sezaki
Yusuke Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co LtdfiledCriticalShionogi and Co Ltd
Priority to US10/239,222priorityCriticalpatent/US20030157174A1/en
Priority claimed from PCT/JP2001/002152external-prioritypatent/WO2001070201A1/en
Assigned to SHIONOGI & CO., LTD.reassignmentSHIONOGI & CO., LTD.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: SUZUKI, YUSUKE, SEZAKI, HAJIME, SYODAI, HIDEKAZU, TSUKADA, TAKAYUKI
Publication of US20030157174A1publicationCriticalpatent/US20030157174A1/en
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

A burst caused by an action of digestive organs can be suppressed and a release of an active ingredient can be controlled without decreasing the dissolution of an active ingredient by adding a water repellent agent into an enteric coat, an inner layer, an outer layer or such layers.

Description

Claims (12)

US10/239,2222000-03-232001-03-19Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent componentAbandonedUS20030157174A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US10/239,222US20030157174A1 (en)2000-03-232001-03-19Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
JP20000813542000-03-23
PCT/JP2001/002152WO2001070201A1 (en)2000-03-232001-03-19Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US10/239,222US20030157174A1 (en)2000-03-232001-03-19Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component

Publications (1)

Publication NumberPublication Date
US20030157174A1true US20030157174A1 (en)2003-08-21

Family

ID=29404659

Family Applications (1)

Application NumberTitlePriority DateFiling Date
US10/239,222AbandonedUS20030157174A1 (en)2000-03-232001-03-19Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component

Country Status (1)

CountryLink
US (1)US20030157174A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20090011020A1 (en)*2005-03-072009-01-08Alfa Wassermann S.P.A.Gastroresistant Pharmaceutical Formulations Containing Rifaximin
US8748447B2 (en)2010-03-052014-06-10Alfa Wassermann S.P.A.Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect
US10258610B2 (en)2011-07-292019-04-16Alfasigma S.P.A.Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections
US10280177B2 (en)2006-09-052019-05-07Alfasigma S.P.A.Use of polyols to obtain stable polymorphous forms of rifaximin
US10428086B2 (en)2014-05-122019-10-01Alfasigma S.P.A.Solvated crystal form of rifaximin, production, compositions and uses thereof
US10703763B2 (en)2005-03-032020-07-07Alfasigma S.P.A.Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Citations (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3432593A (en)*1963-09-181969-03-11Key Pharm IncDelayed and sustained release type pharmaceutical preparation
US4005214A (en)*1974-08-211977-01-25Hoffmann-La Roche Inc.Water-soluble amoxicillin salts
US4828840A (en)*1986-07-171989-05-09Shionogi & Co., Ltd.Sustained-release formulation and production thereof
US5444113A (en)*1988-08-081995-08-22Ecopol, LlcEnd use applications of biodegradable polymers
US6264989B1 (en)*1997-07-232001-07-24Freund Industrial Co., Ltd.Spherical single-substance particles, medicines and foodstuffs containing the particles, and method of production thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3432593A (en)*1963-09-181969-03-11Key Pharm IncDelayed and sustained release type pharmaceutical preparation
US4005214A (en)*1974-08-211977-01-25Hoffmann-La Roche Inc.Water-soluble amoxicillin salts
US4828840A (en)*1986-07-171989-05-09Shionogi & Co., Ltd.Sustained-release formulation and production thereof
US5444113A (en)*1988-08-081995-08-22Ecopol, LlcEnd use applications of biodegradable polymers
US6264989B1 (en)*1997-07-232001-07-24Freund Industrial Co., Ltd.Spherical single-substance particles, medicines and foodstuffs containing the particles, and method of production thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US10703763B2 (en)2005-03-032020-07-07Alfasigma S.P.A.Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US20090011020A1 (en)*2005-03-072009-01-08Alfa Wassermann S.P.A.Gastroresistant Pharmaceutical Formulations Containing Rifaximin
US20100330129A1 (en)*2005-03-072010-12-30Alfa Wassermann S.P.A.Gastroresistant Pharmaceutical Formulations Containing Rifaximin
US8568782B2 (en)*2005-03-072013-10-29Alfa Wassermann S.P.A.Gastroresistant pharmaceutical formulations containing rifaximin
US10285944B2 (en)2005-03-072019-05-14Alfasigma S.P.A.Gastroresistant pharmaceutical formulations containing rifaximin
US10280177B2 (en)2006-09-052019-05-07Alfasigma S.P.A.Use of polyols to obtain stable polymorphous forms of rifaximin
US8748447B2 (en)2010-03-052014-06-10Alfa Wassermann S.P.A.Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect
US10258610B2 (en)2011-07-292019-04-16Alfasigma S.P.A.Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections
US10428086B2 (en)2014-05-122019-10-01Alfasigma S.P.A.Solvated crystal form of rifaximin, production, compositions and uses thereof

Similar Documents

PublicationPublication DateTitle
USRE41148E1 (en)Oral pulsed dose drug delivery system
ES2606463T3 (en) Combination of levodopa / carbidopa immediate release and controlled release dosage forms
EP0533297B1 (en)Controlled-release pharmaceutical formulations
JP2005512997A (en) Tamsulosin tablets
HRP990287A2 (en)Stable complexes of poorly soluble compounds
JP2009513553A (en) Multi-particulate dosage form containing mucoadhesive compositional peptide- or protein-agent and process for making this dosage form
IL136215A (en)Spheroids, preparation method and pharmaceutical compositions
BRPI0513904B1 (en) multiparticulate pharmaceutical form for low solubility active substances and a process for preparing the pharmaceutical form
EP0355247A2 (en)Compressed-molded preparations
JP4540092B2 (en) Pharmaceutical composition containing bioactive compound unstable to acid and process for producing the same
HUT72635A (en)Compositions containing alfuzonin-hydrochloride of sustained release
TW575437B (en)Delayed-release dosage forms of sertraline
PL192648B1 (en)Pharmaceutical with controlled releose containing inhibitor ace as an active substance
US20030157174A1 (en)Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
JP4660192B2 (en) Spheroid, method for producing the same, and pharmaceutical composition
US6399104B1 (en)Pharmaceutical compositions
US20060039997A1 (en)Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
ZA200603656B (en)Controlled-release pharmaceutical formulation
WO2004024128A2 (en)Modified release ketoprofen dosage form
EP1266655A1 (en)Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
JP3929522B2 (en) Sustained release formulation of poorly water-soluble drugs
CA2038400A1 (en)Long acting granular pharmaceutical composition
WO2018102526A1 (en)Pharmaceutical dosage form
JP4603803B2 (en) Controlled release pharmaceutical composition and formulation using the same
AU2006236052B2 (en)Oral pulsed dose drug delivery system

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:SHIONOGI & CO., LTD., JAPAN

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TSUKADA, TAKAYUKI;SYODAI, HIDEKAZU;SEZAKI, HAJIME;AND OTHERS;REEL/FRAME:013489/0482;SIGNING DATES FROM 20020827 TO 20020905

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp